Sentences with phrase «cell receptor targeting»

«This is the first time anyone has succeeded in cloning a T - cell receptor targeting prostate antigen, and we hope we will have an opportunity to test T cells equipped with this receptor in a clinical study.

Not exact matches

Those two companies, along with their larger competitor Novartis (nvs), are developing experimental chimeric antigen receptor T - cell (CAR - T) technology platforms, which are highly personalized treatments that involve extracting patients» immune cells, re-engineering them to target their specific cancers, and then pumping these sniper - cells back into the body.

At the end of September, the European Commission approved a marketing application for Lutathera, a radioactive molecule that targets specific receptors found on the surface of neuroendocrine tumor cells.

CAR T cells target and kill cancer cells via bioengineered T - cell receptors.

Peptides can bind to targets on a cell (usually receptors or enzymes that are themselves proteins) and so regulate cellular functions such as nutrient uptake or communication between cells.

Like many drugs, beta blockers target receptors embedded in the surface of cells.

Each epitope is targeted by a pool of T cells bearing different, but specific, T cell receptors to recognize and respond.

We designed chimeric antigen receptor (CAR) T cells that specifically target podoplanin (PDPN), a key protein for the progression of solid tumors, including GBM.»

This affords safe passage to a theoretically unlimited selection of carriers targeting distinct cell surface receptors.»

When it comes to targeting the disease, because of reduced levels of the serotonin transporters, Smith says, the receptors that detect serotonin on message - receiving cells might be a better option.

A potential adrenalinelike drug for weight control must target only the fat - cell receptors to avoid dangerous side effects in the cardiovascular system.

Lanza also designed the nanoparticles to carry targeting molecules that home in on and bind to cancer cells that carry the complementary receptor, like a lock and key.

To acquire new insights into the biology and possible therapy of these tumors, Feigin et al. looked for aberrant expression of G protein — coupled receptors, cell signaling proteins that have been successfully targeted for treatment of other disorders such as depression.

Around 15 per cent of women with breast cancer have this form of the disease, in which tumour cells lack the three receptors that most drugs target.

T cells genetically engineered to make the chimeric antigen receptor can recognize and target tumor cells.

HIV must bind to both these receptors in early stages of infection in order to slip into the target cells.

Cell lines are the workhorses of biology, routinely stocked and studied in every laboratory to understand cellular pathways, receptors, targets, hormones, and all aspects of normal and malignant physiology.

Liang Xu, Ph.D. member of the KU Cancer Center's Drug Discovery, Delivery and Experimental Therapeutics program and associate professor of molecular biosciences at KU, has discovered that targeting a cell - surface receptor called «CD44s» can block pancreatic tumor formation and recurrence after radiotherapy.

The former target, say, using gene editing techniques to inactivate HIV receptors and achieve resistance of blood cells to the virus (which Sangamo BioSciences is working on in clincial trials) is different than helping parents who both carry genes for Huntington's Disease to have a child that is free of the disease (a change to the genome that would be passed on to future generations and would likely not be very commonly needed).

Chimeric antigen receptor (CAR) T - cell therapies utilize a patient's own T cells that have been genetically engineered to bind to a specific antigen on target cancer cells.

The target for ibrutinib, an enzyme called Bruton's tyrosine kinase (BTK), is a key component of B - cell receptor signaling.

These receptors, called receptor tyrosine kinases (RTKs), transmit instructions through the cell wall and down through a cascade of reactions to a target gene in the nucleus.

They will examine the safety and feasibility of administering cancer - fighting chimeric antigen receptor (CAR) T cells that have been reprogrammed to target the CD22 protein expressed by some leukemia cells.

«Triple - negative breast cancers are cancer cells that lack three receptors targeted by current chemotherapy regimens.

Many investigators had assumed that once breast cancer cells developed resistance to tamoxifen, they would be resistant to all drugs that target the estrogen receptor, McDonnell explained.

Using in vitro, or test tube, experiments, the researchers applied these chemicals to human cancer cells to measure changes of estrogen receptor - and androgen receptor - target genes and transcriptional activity.

In this study, we examined the effectiveness of a vaccination targeting tumors that produced IL - 15 and its cell surface receptor called IL - 15R - alpha -LRB--RRB- and examined their ability to up - regulate (or increase) immune responses to tumor antigens,» Morris says.

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.

Inglis attributes this success to the fact that the bacteriocin targets a receptor on the bacteria's cell surface that is essential to its survival.

One approach is to give patients specific antibodies that target the homing devices (essentially chemical receptors) in white blood cells, rendering the tumor cells immunologically visible.

But only after engaging the target and adjusting their antigen receptors over many generations (as B cells do by mutating their antigen receptor genes) can this lineage of cells produce VRC26 bnAbs.

Once they are engineered with antibodies that bind to specific receptors on the surface of targeted cells, these nanoparticles also can, in principle, become highly specific to the disease they are designed to treat.

Monk also said that Gpr56 belongs to a large class of cell receptors that are common targets for many commercially available drugs, making the protein attractive for further research.

Using newly discovered information, the researchers made significant advances in developing a family of drug candidates that target a receptor known as peroxisome proliferator - activated receptors gamma (PPARγ), a key regulator of stem cells controlling bone formation and bone resorption and a master regulator of fat.

The team led by John Hogenesch, PhD, a professor of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine at University of Pennsylvania and Jason DeBruyne, PhD, a former postdoctoral fellow in the Hogenesch lab and now an assistant professor at Morehouse School of Medicine in Atlanta, applied their new method to identifying other clock partners that target a multipurpose cell nucleus receptor for disposal.

They can be engineered to go into cells and snip any gene a researcher wishes to target (including the gene for the T - cell receptor CCR5).

«If further studies validate that these processes are critical in human breast cancers,» Koshy notes, «the possibility exists that agents that favorably modify the biophysical properties of the extracellular matrix, or that target the receptors and signaling molecules associated with how cells sense this matrix, could be used as a new avenue for the prevention or treatment of breast cancers.»

In human medicine EGFR is frequently used as the target of cancer immunotherapy because many cancer cells bear this receptor on their surface.

Because diseases such as cancer tend to evade detection by T - cells» receptors, allowing a tumor to grow unchecked, scientists have long sought «intel» on this process as a means of developing therapies that target malignant cells, but leave healthy cells alone.

A better understanding of aberrant brain receptor signaling that leads to nerve cell dysfunction could reveal a target for therapy, according to the authors.

The modified T cells contain a protein known as a chimeric antigen receptor (CAR), which is designed to target the CD19 protein found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia and lymphoma.

«We used different groups of mice, in which either the oestrogen receptor or RANKL was inactivated in hematopoietic cells or in mesenchymal cells, to be able to identify the target cells of the hormone.

A study in rats published August 25 in Cell Reports suggests that a different approach that targets delta opioid receptors on sensory neurons in peripheral tissues might avoid the side effects and high abuse potential of currently available pain relievers.

The T cells use their CAR receptors to bind to molecules on target cells, and the act of binding triggers an internal signal that strongly activates the T cells — so that they swiftly destroy their targets.

The artificial receptor acts as a lure for the B cells that target Dsg3, bringing them into fatal contact with the therapeutic T cells.

The resulting treatment consists of four parts: an antibody targeted to the tumor; a vaccine targeted to the tumor; IL - 2; and a molecule that blocks PD1, a receptor found on T cells.

«The vitamin D receptor is expressed in insulin - secreting pancreatic beta cells and in peripheral target tissues such as skeletal muscle and adipose tissue.

The other end, known as the constant region, binds to receptors on the surface of cells that can direct the immune system to respond in a variety of ways, all in the hopes of eliminating the target on the variable end of the antibody.

The researchers, including scientists from pharmaceutical company AstraZeneca, report in an advanced online publication in Nature Medicine on May 4, that their findings indicate «an underappreciated genomic heterogeneity» in mechanisms of resistance to tyrosine kinase inhibitor (TKI) drugs that target the Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases of non-small cell lung cancer (NSCLC).

«The LINK - A dependent HIF1 signalizing cascade and the consequent effects on cancer cells implicate LINK - A and LINK - A interacting kinases and receptors as promising therapeutic targets for TNBC.»